Type 1 diabetes is a chronic disease in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in high blood levels of glucose. A study published January 4th in Cell Stem Cell demonstrates that a gene therapy approach can lead to the long-term survival of functional beta cells as well as normal blood glucose levels for an extended period of time in mice with diabetes. The researchers used an adeno-associated viral (AAV) vector to deliver to the mouse pancreas two proteins, Pdx1 and MafA, which reprogrammed plentiful alpha cells into functional, insulin-producing beta cells.
“This study is essentially the first description of a clinically translatable, simple single intervention in autoimmune diabetes that leads to normal blood sugars, and importantly with no immunosuppression,” says senior study author George Gittes of the University of Pittsburgh School of Medicine. “A clinical trial in both type 1 and type 2 diabetics in the immediate foreseeable future is quite realistic, given the impressive nature of the reversal of the diabetes, along with the feasibility in patients to do AAV gene therapy.”
Approximately 9% of the world’s adult population has diabetes, which can cause serious health problems such as heart disease, nerve damage, eye problems, and kidney disease. One fundamental goal of diabetes treatment is to preserve and restore functional beta cells, thereby replenishing levels of a hormone called insulin, which moves blood glucose into cells to fuel their energy needs. But in patients with type 1 diabetes, beta-cell replacement therapy is likely doomed to failure because the new cells might fall victim to the same autoimmunity that destroyed the original cells.
A potential solution to this problem is to reprogram other cell types into functional beta-like cells, which can produce insulin but are distinct from beta cells and therefore are not recognized or attacked by the immune system. To explore the feasibility of this approach, Gittes and first author Xiangwei Xiao of the University of Pittsburgh School of Medicine engineered an AAV vector to deliver to the mouse pancreas proteins called Pdx1 and MafA, which support beta cell maturation, proliferation, and function. The goal was to generate functional beta-like cells from pancreatic alpha cells, which may be the ideal source for beta cell replacement. For example, alpha cells are plentiful, resemble beta cells, and are in the correct location, all of which could facilitate reprogramming.
By comparing the gene expression patterns of normal beta cells and insulin-producing cells derived from alpha cells, the researchers confirmed nearly complete cellular reprogramming. This gene therapy approach restored normal blood glucose levels in diabetic mice for an extended period of time, typically around four months, and the new insulin-producing cells derived almost exclusively from alpha cells. Moreover, the strategy successfully generated functional insulin-producing cells from human alpha cells.
“The viral gene therapy appears to create these new insulin-producing cells that are relatively resistant to an autoimmune attack,” Gittes says. “This resistance appears to be due to the fact that these new cells are slightly different from normal insulin cells, but not so different that they do not function well.”
Several features of this approach could facilitate translation to humans. For one, AAV vectors like those used in this study are currently undergoing various gene therapy trials in humans. Moreover, the viral vectors can be delivered directly to the human pancreas through a routinely performed non-surgical endoscopic procedure; however, this procedure can elicit pancreatic inflammation. In addition, no immunosuppression is required, so patients would avoid related side effects such as an increased risk of infection.
However, one major concern was that the mice did eventually return to the diabetic state, suggesting that this treatment would not represent a definitive cure for the disease. “The protection from recurrent diabetes in the mice was not permanent, although some studies would suggest that processes in mice are highly accelerated, so four months in mice might translate to several years in humans,” Gittes says.
Currently, the researchers are testing their approach in primates. “If we are able to show efficacy in non-human primates, we will begin work with the FDA to get approval for the use of this viral gene therapy in diabetic patients, both type 1 and type 2,” Gittes says.
The Latest on: Type 1 diabetes
- Intermittent fasting may help reverse type 2 diabetes on October 10, 2018 at 4:05 pm
For one man, this took only five days. RELATED Type 1 diabetes often misdiagnosed in adults Two were able to stop taking all their other diabetes drugs, while the third stopped three of four diabetes ... […]
- JDRF celebrates Health Canada’s new licence for technology that will improve the lives of people with type 1 diabetes on October 10, 2018 at 11:56 am
Approval of Canada’s first Hybrid Closed-Loop System will help Canadians with type 1 diabetes keep their blood sugar levels in an optimal range for a greater amount of time TORONTO, Oct. 10 ... […]
- Bret Michaels to be honored by Diabetes Training Camp Foundation on October 10, 2018 at 11:00 am
The front-man of the acclaimed rock group Poison, Michaels is one of the most recognizable people that is living with Type 1 Diabetes. The rocker will be awarded On November 8, as part of National Dia... […]
- Top endocrinology stories: Type 1 diabetes vaccine explored, vitamin D may improve metabolic syndrome on October 10, 2018 at 5:39 am
The top story in endocrinology this week was the announcement of the potential development of a vaccine to prevent type 1 diabetes following celiac disease research. Other popular stories included fin... […]
- After intermittent fasting, these 3 men no longer take insulin for diabetes — but experts stress caution on October 9, 2018 at 4:09 pm
Ninety to 95% of those cases are Type 2 diabetes. An additional 33.9% of the population, or 84.1 million people, have prediabetes, the agency says. “Diabetes is the No. 1 cause of kidney failure, lowe... […]
- Type 1 diabetes often misdiagnosed in adults on October 9, 2018 at 11:43 am
TUESDAY, Oct. 9, 2018 -- It's not always easy -- even for doctors -- to tell if someone has type 1 or type 2 diabetes when they're diagnosed as an adult. And a new study finds mistakes are common. Tha... […]
- Failing immune system ‘brakes’ help explain type 1 diabetes in mice on October 8, 2018 at 2:31 am
Immune reactions are usually a good thing — the body’s way of eliminating harmful bacteria and other pathogens. But people also rely on molecular “brakes,” or checkpoints, to keep immune systems from ... […]
- Walk to cure type 1 diabetes on October 7, 2018 at 7:35 pm
LA CROSSE, Wis. (WKBT) - - Hundreds gathered in Myrick Park this morning to help find a cure for Type one diabetes. Every year more than 500 people in La Crosse get together for the JDRF one walk to r... […]
- Supporters Out In Force At JDRF Walk To Combat Type 1 Diabetes on October 7, 2018 at 4:31 pm
NEW YORK (CBSNewYork) — Type 1 diabetes doesn’t have a cure — and that’s what keeps a group of walkers coming back year after year to raise money. On Sunday, people with the disease told ... […]
- Local fundraising walk raised $22 million for Type 1 diabetes group within 20 year span on October 7, 2018 at 2:12 pm
ST. LOUIS (KMOV.com) - Throughout the years, there has been huge advances in the technology and research for Type 1 diabetes. And thanks to fundraising efforts at the annual Juvenile Diabetes Research ... […]
via Google News and Bing News